Inovio reports first quarter 2024 financial results and recent business highlights

Bla submission on track for ino-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (rrp) planning initiation of confirmatory trial for ino-3107 based on fda feedback advancing plans for phase 3 trial of ino-3112 in combination with loqtorzitm (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (opscc) based on fda feedback balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in april 2024 cash runway projected into third quarter of 2025 plymouth meeting, pa. , may 13, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.
INO Ratings Summary
INO Quant Ranking